anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study aimed to report the outcomes of active surveillance (AS) in the management of low-risk prostate cancer (PCa). It recruited 87 men who were prospectively followed up according to the Prostate Cancer Research International Active Surveillance (PRIAS) protocol with local adaptation at SH Ho Urology Centre, Prince of Wales Hospital, Hong Kong, China. We investigated the predictors of disease progression and found that baseline prostate-specific antigen density (PSAD) and the presence of the highest Prostate Imaging-Reporting and Data System (PI-RADS) score 5 lesion on magnetic resonance imaging (MRI) are significantly correlated with disease progression. Moreover, men with PSAD >0.2 ng ml -2 or PI-RADS 4 or 5 lesions had significantly worse upgrading-free survival compared to those with PSAD ≤0.2 ng ml -2 and PI-RADS 2 or 3 lesions. The study concludes that AS is a safe and effective management strategy for selected patients to defer radical treatment and that most disease progression can be detected after the first repeated biopsy. The combination of PSAD >0.2 ng ml -2 and PI-RADS 4 or 5 lesions may serve as a useful predictor of early disease progression and provide a guide to optimize follow-up protocols for men in different risk groups.
A system, a computerized apparatus and a method for drowning detection based on swimmer analytics. The method comprises obtaining a visual input cameras observing a water area and analyzing each swimmer in the water area based on the visual input. Said analyzing comprises determining a risk level of each swimmer, whereby a first risk level is determined for a first swimmer and a second risk level is determined for a second swimmer, wherein the first risk level is higher than the second risk level; and automatically detecting potential drowning events for each swimmer. Said automatically detecting is performed by utilizing computational resources in a non-uniform manner. Said automatically detecting comprises applying increased computational resources with respect to the first swimmer, and applying reduced computational resources with respect to the second swimmer. The increased computational resources are higher than the reduced computational resources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of the global population, with a significant risk of advancing to liver cirrhosis and hepatocellular carcinoma. The roles of ammonia and glutamine in MASLD's pathogenesis are increasingly recognized, prompting this systematic review. This systematic review was conducted through a meticulous search of literature on December 21, 2023, across five major databases, focusing on studies that addressed the relationship between ammonia or glutamine and MASLD. The quality of the included studies was evaluated using CASP checklists. This study is officially registered in the PROSPERO database (CRD42023495619) and was conducted without external funding or sponsorship. Following PRISMA guidelines, 13 studies were included in this review. The studies were conducted globally, with varying sample sizes and study designs. The appraisal indicated a mainly low bias, confirming the reliability of the evidence. Glutamine's involvement in MASLD emerged as multifaceted, with its metabolic role being critical for liver function and disease progression. Variable expressions of glutamine synthetase and glutaminase enzymes highlight metabolic complexity whereas ammonia's impact through urea cycle dysfunction suggests avenues for therapeutic intervention. However, human clinical trials are lacking. This review emphasizes the necessity of glutamine and ammonia in understanding MASLD and identifies potential therapeutic targets. The current evidence, while robust, points to the need for human studies to corroborate preclinical findings. A personalized approach to treatment, informed by metabolic differences in MASLD patients, is advocated, alongside future large-scale clinical trials for a deeper exploration into these metabolic pathways.
The present invention belongs to the field of Chinese medicines, which particularly relates to a compound preparation for treating osteoarthropathy and a preparation method thereof. The compound preparation for treating osteoarthropathy is prepared from Chinese medicinal materials such as white peony root, largeleaf gentian root, oyster shell, liquorice root, scolopendra and scorpion as main medicines and auxiliary materials according to a quantitative proportion. Experiment indicates that a high, medium and low dose of the Chinese medicinal compound preparation of the present invention has the functions of resisting inflammation and alleviating pain. The observation to pathological histomorphology of cartilage verifies that the compound preparation can improve the density and the thickness of cartilage cells to lower integrals of osteoarthropathy, delay cartilage degradation and enhance the SOD content of C57 primary OA blood serum of black rats to lower NO and HA contents. The compound preparation has the function of protection cartilage degradation. The preparation method disclosed by the present invention can reserve effective components in medicinal materials with high efficiency and simplify the preparation technology of Chinese medicinal preparations and is favorable to the operation of mass production.
The present invention by provides a system for treating the symptoms of a user having a bad breath or taste after drinking a liquid substance. The invention comprises a drink container initially containing the liquid substance consumed by the user. A breath strip assembly forming a strip pouch is carried by the drink container. A single soluble film breath strip is housed in the strip pouch to be accessed by the user and dissolved in the mouth to remove the users bad breath and taste. In one aspect the breath strip assembly comprises a flexible substrate having front and rear surfaces. The rear surface is attached to the drink container using a pressure sensitive rear adhesive between the rear surface and the drink container. A removable film is partially attached to the front surface of the substrate using a pressure sensitive front adhesive on the substrate in a pattern to provide the strip pouch.
Checkpoint Inhibitor (CPI)-Naïve Participants with non-small-cell lung cancer (NSCLC) who have not received CPI therapy previously will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: collection of fresh tumor biopsies (at baseline and on-treatment) will be optional.
Background and Objectives: Sarcopenic obesity, a clinical condition coexisting with obesity and sarcopenia, is associated with a high risk of functional impairment, reduced quality of life, and increased mortality. A decline in age-related free testosterone (FT) levels has been reported to be associated with decreased muscle mass and muscle strength and increased fat mass. However, the association between low FT levels and risk of sarcopenic obesity has not been well studied. This study aimed to investigate the direct association between low FT levels and sarcopenic obesity. Materials and Methods: This cross-sectional study used data of 982 community-dwelling men aged 70-84 years from the Korean Frailty and Aging Cohort Study. Sarcopenia was defined according to the criteria of the Asian Group for Sarcopenia (AWGS) 2019. Obesity was defined as a body fat mass ≥28.3%. Participants who met both sarcopenia and obesity criteria were defined as having sarcopenic obesity. Low FT levels were defined as FT levels <17.35 pmol/L according to the Endocrine Society Clinical Practice Guidelines. Results: The prevalence of sarcopenia, obesity, and sarcopenic obesity was significantly higher in the low-FT group than in the normal-FT group. Low FT levels were significantly associated with a higher risk of obesity (odds ratio [OR], 2.09, 95% confidence interval [CI], 1.11-3.92), sarcopenia (2.57, 95% CI 1.08-6.10), and sarcopenic obesity (3.66, 95% CI 1.58-8.47) compared with the healthy control group. The risk of low appendicular skeletal muscle mass index (ASMI) (1.78, 95% CI 1.04-3.02) and high fat mass (1.92, 95% CI 1.12-3.31) was significantly higher in the low-FT group than in the normal-FT group. Conclusions: This study showed that low FT levels were associated with a higher risk of sarcopenic obesity. Low FT levels were mainly related to body composition parameters such as low ASMI and high fat mass.
EBV-infection is a well-known trigger of CFS. A closely related research project (Chronic fatigue following acute Epstein-Barr virus infection in Adolescents; ClinicalTrials ID:NCT02335437) is a combined prospective and cross-sectional study of 200 adolescents suffering from acute EBV infection. The primary aim of that study is to identify factors that predispose to CFS 6 months after the acute infection. Thus, that project will provide a sample of thoroughly characterized CFS patients, all having the same precipitation factor (EBV-infection).

The present project is an intervention trial in the subgroup of patients that actually did develop CFS 6 months after the acute EBV infection. Patients will be randomised 1:1 to either a mental training program (10 sessions) combining elements from cognitive behavioral therapy and music therapy, or routine follow-up from the general practitioner. By its nature, treatment group allocation cannot be blinded; however, both patients and therapists will be blinded for end-point evaluation. An extensive investigational program will be carried out at three time points: Prior to the intervention, immediately after the intervention, and 1 year after the intervention. The program includes: Clinical examination; Pain threshold assessment; Cardiovascular assessment; Cognitive assessment; Sampling of biological material (blood and urine); Questionnaire; Brain fMRI; Qualitative interview; Monitoring of physical activity (accelerometer)
The utility model relates to a herbal composition for treating erectile dysfunction comprising combination of Eurycoma longifolia, Moringa oleifera and Mimosa pudica. Extracted roots of Mimosa pudica, Eurycoma longifolia and young pods of Moringa oleifera were screened and tested for their active constituents in treating erectile dysfunction in mammals using laboratory mice. Phytochemical analysis shows the presence of several bioactive compounds from the combined extract of these plants. The common constituents found are flavonoids, alkaloids, amino acid, tannins, glycosides, saponins, tripenoid, glycoprotein, and polysaccharides. Individual plant extracts reported are glycosinolates, isothiocyanates, benzyl isothiocyanate niagimisin in M. pudica, zeain, quercetin, beta-sitosterol, caffeoylquinic acid and kempfero in M. oleifera, and eurycomanone, B-carbolin. eurycomanol, eurycomalactone, propionic acid and campesterol in E. longifolia.
The study has been approved by our Institutional IRB and conducted in accordance with the principles of the Declaration of Helsinki. The trial will be registered at Clinicaltrials.gov, a service of the U.S. National Institutes of Health. There is equipoise. This randomized controlled trial will compare the effectiveness of VR in in patients with PTSD who have suffered combat related traumatic brain injuries. A blinded investigator that will not be involved in the study will perform the randomization and allocation procedure.

We will accomplish the specific aim of our study by analyzing the difference in the Clinician Administered DSM-IV PTSD Scale (CAPS) scores between the two groups in our study as outcomes to compare the effectiveness of VR. The CAPS is considered to be the gold standard for diagnosing PTSD and assessing symptom severity. We expect differences in the outcomes between both treatments to be immediate and at follow-up over time, i.e. immediately after 3 months, 6 months and 12 months after cessation of a 2 week treatment period. The study design will include one pre-treatment assessment and our post-treatment assessments (at 3 months, 6 months and 12 months). Investigators who will be blinded for the allocated treatment will perform all assessments. The study will be performed at the department of Neurology of our Institutional Brain Center in Dallas, Texas. Patient recruitment will begin starting in September 2014.
The swimming pool arrangement filled with water and nano-ozone ball for rehabilitation, comprises a bath (10), a reservoir (30), circulation systems and a gas-generating device having an oxygen generator (22), and an ozone generator (23) connected with the oxygen generator. The bath comprises a side, a top, a bottom, an inner area, main inlet and outlet connected with the inner area, an overflow arranged on the side and near to the upper part of the bath, and an overflow pipeline arranged on the bottom of the bath and connected with the inner area. The swimming pool arrangement filled with water and nano-ozone ball for rehabilitation, comprises a bath (10), a reservoir (30), circulation systems and a gas-generating device having an oxygen generator (22) and an ozone generator (23) connected with the oxygen generator. The bath comprises a side, a top, a bottom, an inner area, main inlet and outlet connected with the inner area, an overflow arranged on the side and near to the upper part of the bath, and an overflow pipeline arranged on the bottom of the bath and connected with the inner area. The overflow of the bath is connected with the inner area of the bath. The reservoir comprises a side, a top, a bottom, an inner area, main inlet and outlet connected with the inner area of the reservoir, an overflow arranged on the side and near to the upper part of the reservoir, an overflow pipeline arranged on the bottom of the reservoir and connected with the inner area of the reservoir, and a water conduit connected with the inner area of the reservoir. The overflow of the reservoir is connected with the inner area of the reservoir. The circulation system shows a bath that is connected with another circulation system with the reservoir and that has a filter (21) connected with the main outlet of the bath or the reservoir, a high pressure pump connected with the filter of either the bath or the reservoir by a pipeline and also connected with the ozone generator, constant voltage regulators (25) connected with the high pressure pump, and a high pressure emulsifying device connected with the voltage regulator by a pipeline and also connected with the main inlets. The high-pressure pump is connected with the circulation systems by a connection pipeline and shows a tape water inlet and two valves. Each valve is arranged between either the high-pressure pumps or the tape water inlets. Each voltage regulators shows an air extraction valve. Each emulsifying device shows a control valve. The main inlets and outlets of the bath and of the reservoir exhibit valves. The overflow pipeline of the bath and the reservoir exhibit clasps.
Novel methods and storage media for storing platelets in a viable condition for at least five days. The methods comprise the steps of providing a platelet rich suspension of platelets and blood plasma; extracting supernatant plasma from that suspension to leave between about 1 to 15 mls of plasma per unit of blood platelets with those platelets to produce a concentrated platelet button; adding 40 to 70 ml/unit of a glucose free aqueous solution to said concentrated platelet button; agitating the resultant solution to resuspend the platelets to provide a synthetic suspension of those platelets; and storing that synthetic suspension in an oxygen permeable container at about 22°C. until needed for use. Two preferred glucose free aqueous platelet storage media are disclosed which generally comprise sodium citrate, sodium chloride, potassium chloride, and either sodium phosphate or calcium chloride, but not both. The subject media also optionally comprise magnesium sulfate. Results comparable to storing blood platelets in plasma are disclosed using media which free plasma for other uses and which may reduce the risk of disease transmission from platelet infusion.
In the experimental groups the education whose content (definition and importance of violence and conflict, violence against women, the cycle of violence, who is at risk for violence, characteristics of perpetrators and the victims of violence, types of violence against women, consequences of violence and conflict on individuals, legal aspects of violence, positive coping with violence and conflict, empowering women against violence, conflict resolution) was prepared by the researcher in line with the adult education principles and pertinent literature was given in the school prepared for education beforehand. In accordance with the adult education principles, the students were educated in groups of 12-15 people. During the education, methods such as narration, discussion, question-answer, brainstorming, problem solving and summarizing, data shows, brochures, posters and visual materials were used. The duration of the education lasted 30-40 minutes.
The aim of this study is to determining of the effects of Eicosapentaenoic acid (EPA) supplementation on serum activities of Paraoxonase-1 and Homocystein thiolactonase and several indicators of vascular inflammation and the gene expression of PON2 in the peripheral blood mononuclear cell (PBMC) in the patients with type II diabetes mellitus. In this randomized, double-blind clinical trial, placebo-controlled, single-center, 36 men and women aged 35-50 years with type 2 diabetes are enrolled in the study from the Iranian Diabetes Association. After signing informed consent, all individuals complete a general information form. a 24-hour food recall for 3 days will be taken from the participants at the beginning and the end of the study,. Selected samples are randomly classified into 2 blocks of groups receiving supplement and placebo. Two groups will be classified (blocked) based on sex. The supplement group, will receive 2 g/day EPA for 8 weeks and the placebo group will also receive placebo (containing 2 g of edible paraffin) (similar in terms of color, shape and size). Patients are recommended to sustain their diets and medication dose (s) during the study and also advised to maintain a constant level of physical activity. Blood samples will be collected after 8-12 hours fasting and anthropocentric variables, biochemical parameters, target gene expression and physical activity before and after the trial will be measured.
A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.
PURPOSE:To progress automation, to prevent mistake and to improve the reading speed by continuous reading by providing a patient name read means and reading a patient name printed on a corner or an edge of an X-ray film together with a picture. CONSTITUTION:The picture of the X-ray film and the patient name printed at the corner or the edge of the film inputted via a linear CCD line sensor 19 are digitized through a logarithmic convering section 24 and an A/D converter 26. The digitized data is inputted to a patient name read circuit 27 and the patient name and a patient number printed on the X-ray film via a handwriting character reader incorporated in the circuit 27 are read automatically. The picture read and the patient name, etc. are inputted to a computer via an I/O28 next. The patient name reading circuit 27 is provided in this way and the patient name is automatically together with the picture, allowing to progress automation, prevent mistage and improve the reading speed because of continuous reading.
PURPOSE: A composition containing Pterocladiella capillacea extract is provided to ensure skin whitening effect and to be applied to a cosmetic, pharmaceutical, or food composition without side effect. CONSTITUTION: A composition for skin whitening contains Pterocladiella capillacea extract as an active ingredient. The composition additionally contains 0.001-20.0 wt% of taxifolin as an active ingredient. The extract and taxifolin is mixed in a weight ratio of 0.5:1-1.5:1. The composition is a cosmetic composition manufactured in the form of a solution, suspension, emulsion, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, or spray. The composition is also a pharmaceutical or food composition.
The hospital procedure was applied to determine the birth rates of all pregnant women in the control group. From the latent stage until the birth, the pregnant woman is followed up by applying the hospital procedure. At the end of the latent and active phases, the alarm results were requested to be evaluated and VAS (Appendix 6) was developed. The 2nd and 3rd stages of labor were performed in the lithotomy positions on the normal delivery table.
Primary systemic vasculitis associated with autoantibodies to neutrophil cytoplasmic antigens (ANCA), is the most frequent cause of rapidly progressive glomerulonephritis. Renal failure at presentation often progresses to end stage renal disease despite immunosuppressive therapy. We investigated whether the addition of plasma exchange was more effective than intravenous (IV) methyl prednisolone in the achievement of renal recovery for ANCA associated systemic vasculitis presenting with a serum creatinine above 500umol/l (5.8mg/dl).

137 patients with a new diagnosis of ANCA associated systemic vasculitis, serum creatinine above 500umol/l (5.8mg/dl) and a renal biopsy demonstrating a focal, necrotizing glomerulonephritis were randomized to receive seven plasma exchanges or IV methyl prednisolone 1000mg/day for three days. Both groups were treated with cyclophosphamide and oral prednisolone. The primary end-point was dialysis independence with a serum creatinine below 500umol/l (5.8mg/dl) at three months. Secondary end-points included renal and patient survival at 12 months and severe adverse event rates.
PURPOSE OF REVIEW: Worsening heart failure (WHF) has developed as a unique definition within heart failure (HF) in recent years. It captures the disease as a dynamic process. This review describes what is currently known about WHF, why it should be considered a discrete scientific endpoint, and future directions for research.
RECENT FINDINGS: There is no single agreed upon definition for WHF. It can be identified as being due to treatment side-effects, related to concomitant comorbidity, or true disease progression. Risk scores based on criteria like those already developed for HF can be created to stratify risk for WHF.
CONCLUSIONS: WHF is an emerging entity within HF that defines itself as a unique point of interest. Understanding it as a clinical measure of where a patient's HF is evolving allows for identifying patients that require a refreshed approach to their care. Keeping this in mind will help redefine more patient-centric outcome measures in research to come.